Top

02-01-2018 | Bladder cancer | Article

Characteristics and clinical significance of histological variants of bladder cancer

Journal: Nature Reviews Urology

Authors: Marco Moschini, David D'Andrea, Stephan Korn, Yasin Irmak, Francesco Soria, Eva Compérat, Shahrokh F Shariat

Authors: Marco Moschini, David D'Andrea, Stephan Korn, Yasin Irmak, Francesco Soria, Eva Compérat, Shahrokh F. Shariat

Publisher: Nature Publishing Group UK

Abstract

In the past 10 years evidence for the clinical relevance of variant histology in urinary bladder cancer has been increasing. This increase has resulted in new classifications of urothelial cancers by the WHO in 2016, highlighting the importance of an accurate morphological description of pathological specimens for the therapeutic management of patients with bladder cancer. The rising awareness of the importance of an accurate pathological report manifests itself in the increasing prevalence of reporting of variant histology in daily practice. Histological variants can generally be divided into urothelial and nonurothelial. Urothelial variants often have similar features that also have specific morphological phenotypes, whereas nonurothelial variants have independent features. Overall, histological variants follow a more aggressive clinical course than conventional urothelial carcinoma, but conclusive data on their effect on survival are currently lacking. The clinical relevance of variant histology can manifest at three different levels: diagnostic, as identification is challenging and misinterpretation is not uncommon; prognostic, for patient risk stratification and outcome estimation; and therapeutic, as particular variants could be responsive to specific treatment strategies. An accurate morphological description of histological variants is necessary for patient consultation and therapy planning. Moreover, the association of variant histology with specific mutation patterns promises to be helpful in discovering targeted therapeutic approaches based on specific molecular pathways.

Nat Rev Urol 2017; 14:651–668. doi:10.1038/nrurol.2017.125

Wasco, M. J. et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology 70, 69–74 (2007).PubMed

Cai, T. et al. Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens. Urology 84, 1141–1146 (2014).PubMed

International Agency for Research on Cancer. WHO Classification of Tumours of the Urinary System and Male Genital Organs (eds Moch, H., Humphrey, P. A., Ulbright, T. M. & Reueter, V. E.) (WHO, 2016).

Shah, R. B., Montgomery, J. S., Montie, J. E. & Kunju, L. P. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol. Oncol. 31, 1650–1655 (2013).PubMed

Monn, M. F. et al. Contemporary bladder cancer: variant histology may be a significant driver of disease. Urol. Oncol. 33, 18.e15–18.e20 (2015).

Kaimakliotis, H. Z. et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol. Oncol. 32, 833–838 (2014).PubMed

Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol. 71, 447–461 (2017).PubMed

Alfred Witjes, J. et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 71, 462–475 (2016).PubMed

Chang, S. S. et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J. Urol. http://dx.doi.org/10.1016/j.juro.2017.04.086 (2017).

10.

Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur. Urol. 70, 106–119 (2016).PubMed

11.

Rice, K. R. et al. Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology. Urol. Oncol. 33, 20.e23–20.e29 (2015).

12.

Abol-Enein, H., Kava, B. R. & Carmack, A. J. K. Nonurothelial cancer of the bladder. Urology 69, 93–104 (2007).PubMed

13.

Felix, A. S. et al. The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control 19, 421–429 (2008).PubMedPubMedCentral

14.

Guo, C. C. et al. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum. Pathol. 40, 1448–1452 (2009).PubMed

15.

Lopez-Beltran, A. & Cheng, L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum. Pathol. 37, 1371–1388 (2006).PubMed

16.

Ehdaie, B. et al. Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. J. Urol. 187, 74–79 (2012).PubMed

17.

Lagwinski, N. et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am. J. Surg. Pathol. 31, 1777–1787 (2007).PubMed

18.

Rambau, P., Chalya, P. L. & Jackson, K. Schistosomiasis and urinary bladder cancer in North Western Tanzania: a retrospective review of 185 patients. Infecti. Agents Cancer 8, 19 (2013).

19.

Salem, H. K. & Mahfouz, S. Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology 79, 379–383 (2012).PubMed

20.

Mouli, S., Casalino, D. D. & Nikolaidis, P. Imaging features of common and uncommon bladder neoplasms. Radiol. Clin. North Amer. 50, 301–316 (2012).

21.

Gaisa, N. T. et al. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Archiv: Int. J. Pathol. 458, 301–312 (2011).

22.

el-Mekresh, M. M., el-Baz, M. A., Abol-Enein, H. & Ghoneim, M. A. Primary adenocarcinoma of the urinary bladder: a report of 185 cases. Br. J. Urol. 82, 206–212 (1998).PubMed

23.

Zaghloul, M. S. et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol. Oncol. 24, 13–20 (2006).PubMed

24.

Grignon, D. J., Ro, J. Y., Ayala, A. G., Johnson, D. E. & Ordóñez, N. G. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 67, 2165–2172 (1991).PubMed

25.

Grignon, D. J., Ro, J. Y., Ayala, A. G. & Johnson, D. E. Primary signet-ring cell carcinoma of the urinary bladder. Am. J. Clin. Pathol. 95, 13–20 (1991).PubMed

26.

Amin, M. B. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod. Pathol. 22 (Suppl. 2), S96–S118 (2009).PubMed

27.

Kim, S. P. et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J. Urol. 188, 405–409 (2012).PubMed

28.

Purnell, S., Sidana, A., Maruf, M., Grant, C. & Agarwal, P. K. Genitourinary paraganglioma: demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database. Urol. Oncol. 35, 457.e9–457.e14 (2017).

29.

Sved, P., Gomez, P., Manoharan, M., Civantos, F. & Soloway, M. S. Small cell carcinoma of the bladder. BJU Int. 94, 12–17 (2004).PubMed

30.

Ploeg, M. et al. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J. Urol. 183, 915–920 (2010).PubMed

31.

Koay, E. J., Teh, B. S., Paulino, A. C. & Butler, E. B. A. Surveillance, epidemiology, and end results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. Cancer 117, 5325–5333 (2011).PubMed

32.

Abrahams, N. A., Moran, C., Reyes, A. O., Siefker-Radtke, A. & Ayala, A. G. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 46, 57–63 (2005).PubMed

33.

Abbas, F., Civantos, F., Benedetto, P. & Soloway, M. S. Small cell carcinoma of the bladder and prostate. URL 46, 617–630 (1995).

34.

Choong, N. W. W., Quevedo, J. F. & Kaur, J. S. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 103, 1172–1178 (2005).PubMed

35.

Mukesh, M., Cook, N., Hollingdale, A. E., Ainsworth, N. L. & Russell, S. G. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int. 103, 747–752 (2009).PubMed

36.

Trias, I. et al. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur. Urol. 39, 85–90 (2001).PubMed

37.

Cheng, L. et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 101, 957–962 (2004).PubMed

38.

Quek, M. L. et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J. Urol. 174, 93–96 (2005).PubMed

39.

Siefker-Radtke, A. O. et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J. Urol. 172, 481–484 (2004).PubMed

40.

Compérat, E. et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology 42, 650–654 (2010).PubMed

41.

Kamat, A. M. et al. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110, 62–67 (2007).PubMed

42.

Amin, M. B. et al. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am. J. Surg. Pathol. 18, 1224–1232 (1994).PubMed

43.

Sangoi, A. R. et al. Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am. J. Surg. Pathol. 34, 1367–1376 (2010).PubMed

44.

Guo, C. C. et al. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur. Urol. 70, 611–620 (2016).PubMedPubMedCentral

45.

Watts, K. E. & Hansel, D. E. Emerging concepts in micropapillary urothelial carcinoma. Adv. Anatom. Pathol. 17, 182–186 (2010).

46.

Summerhayes, I. C. et al. Clinical and pathological characteristics of micropapillary transitional cell carcinoma: a highly aggressive variant. J. Urol. 163, 748–751 (2000).PubMed

47.

Kamat, A. M. et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J. Urol. 175, 881–885 (2006).PubMed

48.

Sui, W. et al. Micropapillary bladder cancer: insights from the National Cancer Database. Bladder Cancer 2, 415–423 (2016).PubMedPubMedCentral

49.

Spaliviero, M. et al. Clinical outcome of patients with T1 micropapillary urothelial carcinoma of the bladder. J. Urol. 192, 702–707 (2014).PubMedPubMedCentral

50.

Willis, D. L. et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol. Oncol. 32, 826–832 (2014).PubMedPubMedCentral

51.

Wright, J. L. et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J. Urol. 178, 2302–2306 (2007).PubMed

52.

Cheng, L. et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am. J. Surg. Pathol. 35, e34–e46 (2011).PubMed

53.

Jones, E. C. & Young, R. H. Myxoid and sclerosing sarcomatoid transitional cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 25 cases. Mod. Pathol. 10, 908–916 (1997).PubMed

54.

Gronau, S. et al. Immunohistomorphologic and molecular cytogenetic analysis of a carcinosarcoma of the urinary bladder. Virchows Arch. 440, 436–440 (2002).PubMed

55.

Lopez-Beltran, A., Luque, R. J., Mazzucchelli, R., Scarpelli, M. & Montironi, R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J. Clin. Pathol. 55, 641–647 (2002).PubMedPubMedCentral

56.

Mukhopadhyay, S., Shrimpton, A. E., Jones, L. A., Nsouli, I. S. & Abraham, N. Z. Carcinosarcoma of the urinary bladder following cyclophosphamide therapy: evidence for monoclonal origin and chromosome 9p allelic loss. Arch. Pathol. Lab. Med. 128, e8–e11 (2004).PubMed

57.

Stamatiou, K. et al. Sarcomatoid carcinoma of the urinary bladder: a clinicopathological study of 4 cases and a review of the literature. Kor. J. Urol. 51, 724–728 (2010).

58.

Wang, J., Wang, F. W., Lagrange, C. A., Hemstreet Iii, G. P. & Kessinger, A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma 2010, 454792 (2010).PubMedPubMedCentral

59.

Malla, M., Wang, J. F., Trepeta, R., Feng, A. & Wang, J. Sarcomatoid carcinoma of the urinary bladder. Clin. Genitourinary Cancer 14, 366–372 (2016).

60.

Moschini, M. et al. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol. Oncol. 35, 335–341 (2017).PubMed

61.

Lopez-Beltran, A., Requena, M. J., Montironi, R., Blanca, A. & Cheng, L. Plasmacytoid urothelial carcinoma of the bladder. Hum. Pathol. 40, 1023–1028 (2009).PubMed

62.

Dayyani, F. et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J. Urol. 189, 1656–1661 (2013).PubMed

63.

Kaimakliotis, H. Z. et al. Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology 83, 1112–1116 (2014).PubMed

64.

Ricardo-Gonzalez, R. R. et al. Plasmacytoid carcinoma of the bladder: a urothelial carcinoma variant with a predilection for intraperitoneal spread. J. Urol. 187, 852–855 (2012).PubMed

65.

Keck, B. et al. Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy. BMC Cancer 13, 71 (2013).PubMedPubMedCentral

66.

Amin, M. B. et al. Lymphoepithelioma-like carcinoma of the urinary bladder. Am. J. Surg. Pathol. 18, 466–473 (1994).PubMed

67.

Fadare, O., Renshaw, I. L. & Rubin, C. Pleomorphic lymphoepithelioma-like carcinoma of the urinary bladder. Int. J. Clin. Exp. Pathol. 2, 194–199 (2009).PubMed

68.

Lopez-Beltran, A. et al. Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. Virchows Archiv: Int. J. Pathol. 438, 552–557 (2001).

69.

Williamson, S. R. et al. Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. Am. J. Surg. Pathol. 35, 474–483 (2011).PubMed

70.

Pantelides, N. et al. Lymphoepithelioma-like carcinoma of the urinary bladder: a case report and review of systemic treatment options. Urol. Ann. 4, 45 (2012).PubMedPubMedCentral

71.

Talbert, M. L. & Young, R. H. Carcinomas of the urinary bladder with deceptively benign-appearing foci. A report of three cases. Am. J. Surg. Pathol. 13, 374–381 (1989).PubMed

72.

Young, R. H. & Oliva, E. Transitional cell carcinomas of the urinary bladder that may be underdiagnosed. A report of four invasive cases exemplifying the homology between neoplastic and non-neoplastic transitional cell lesions. Am. J. Surg. Pathol. 20, 1448–1454 (1996).PubMed

73.

Beltran, A. L. et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch. 465, 199–205 (2014).PubMed

74.

Cox, R. & Epstein, J. I. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma. Am. J. Surg. Pathol. 35, 1337–1342 (2011).PubMed

75.

Holmang, S. & Johansson, S. L. The nested variant of transitional cell carcinoma—a rare neoplasm with poor prognosis. Scand. J. Urol. Nephrol. 35, 102–105 (2001).PubMed

76.

Wasco, M. J., Daignault, S., Bradley, D. & Shah, R. B. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 30 pure and mixed cases. Hum. Pathol. 41, 163–171 (2010).PubMed

77.

Linder, B. J. et al. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J. Urol. 189, 1670–1675 (2013).PubMed

78.

Young, R. H. & Zukerberg, L. R. Microcystic transitional cell carcinomas of the urinary bladder. A report of four cases. Am. J. Clin. Pathol. 96, 635–639 (1991).PubMed

79.

Lopez-Beltran, A., Montironi, R. & Cheng, L. Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. Histopathology 64, 872–879 (2014).PubMed

80.

Mai, K. T., Hakim, S. W., Ball, C. G., Flood, T. A. & Belanger, E. C. Nested and microcystic variants of urothelial carcinoma displaying immunohistochemical features of basal-like urothelial cells: an immunohistochemical and histopathogenetic study. Pathol. Int. 64, 375–381 (2014).PubMed

81.

Lopez-Beltran, A., Blanca, A., Montironi, R., Cheng, L. & Regueiro, J. C. Pleomorphic giant cell carcinoma of the urinary bladder. Hum. Pathol. 40, 1461–1466 (2009).PubMed

82.

Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E. & Ulbright, T. M. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur. Urol. 70, 93–105 (2016).PubMed

83.

Lopez-Beltran, A. et al. Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. Am. J. Surg. Pathol. 34, 371–376 (2010).PubMed

84.

Kojima, Y. et al. A case of urothelial carcinoma, lipid cell variant. Pathol. Int. 63, 183–187 (2013).PubMed

85.

Yamashita, R., Yamaguchi, R., Yuen, K., Niwakawa, M. & Tobisu, K. Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain. Int. J. Urol. 13, 1448–1450 (2006).PubMed

86.

Rotellini, M., Fondi, C., Paglierani, M., Stomaci, N. & Raspollini, M. R. Clear cell carcinoma of the bladder in a patient with a earlier clear cell renal cell carcinoma: a case report with morphologic, immunohistochemical, and cytogenetical analysis. Appl. Immunohistochem. Mol. Morphol. 18, 396–399 (2010).

87.

Young, R. H. & Scully, R. E. Clear cell adenocarcinoma of the bladder and urethra. A report of three cases and review of the literature. Am. J. Surg. Pathol. 9, 816–826 (1985).PubMed

88.

Venyo, A. K.-G. Primary clear cell carcinoma of the urinary bladder. Int. Scholarly Res. Notices 2014, 1–15 (2014).

89.

Adeniran, A. J. & Tamboli, P. Clear cell adenocarcinoma of the urinary bladder: a short review. Arch. Pathol. Lab. Med. 133, 987–991 (2009).PubMed

90.

Moschini, M. et al. Pure but not mixed histologic variants are associated with poor survival at radical cystectomy in bladder cancer patients. Clin. Genitourin. Cancer http://dx.doi.org/10.1016/j.clgc.2016.12.006 (2016).

91.

Manunta, A., Vincendeau, S., Kiriakou, G., Lobel, B. & Guillé, F. Non-transitional cell bladder carcinomas. BJU Int. 95, 497–502 (2005).PubMed

92.

Izard, J. P. et al. Outcomes of squamous histology in bladder cancer: a population-based study. Urol. Oncol. 33, 425.e7–425.e13 (2015).

93.

Kantor, A. F., Hartge, P., Hoover, R. N. & Fraumeni, J. F. Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res. 48, 3853–3855 (1988).PubMed

94.

Scosyrev, E., Yao, J. & Messing, E. Urothelial carcinoma versus squamous cell carcinoma of bladder: is survival different with stage adjustment? Urology 73, 822–827 (2009).PubMed

95.

Abdollah, F. et al. Survival after radical cystectomy of non-bilharzial squamous cell carcinoma versus urothelial carcinoma: a competing-risks analysis. BJU Int. 109, 564–569 (2012).PubMed

96.

Williamson, S. R., Lopez-Beltran, A., Montironi, R. & Cheng, L. Glandular lesions of the urinary bladder:clinical significance and differential diagnosis. Histopathology 58, 811–834 (2011).PubMed

97.

Galsky, M. D. et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 69, 255–259 (2007).PubMed

98.

Lughezzani, G. et al. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology 75, 376–381 (2010).PubMed

99.

Mills, S. E. et al. Small cell undifferentiated carcinoma of the urinary bladder. A light-microscopic, immunocytochemical, and ultrastructural study of 12 cases. Am. J. Surg. Pathol. 11, 606–617 (1987).PubMed

100.

Soria, F. et al. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World J. Urol. 35, 251–259 (2016).PubMed

101.

Ross, J. S. et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin. Cancer Res. 20, 68–75 (2014).PubMed

102.

Ching, C. B. et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod. Pathol 24, 1111–1119 (2011).PubMed

103.

Kim, B. et al. HER2 protein overexpression and gene amplification in plasmacytoid urothelial carcinoma of the urinary bladder. Dis. Markers 2016, 8463731–8463736 (2016).PubMedPubMedCentral

104.

Schneider, S. A. et al. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod. Pathol. 27, 758–764 (2014).PubMed

105.

de Martino, M. et al. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biol. Ther. 15, 1239–1247 (2014).PubMedPubMedCentral

106.

Wülfing, C. et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115, 2881–2890 (2009).PubMed

107.

Lim, M. G., Adsay, N. V., Grignon, D. J. & Osunkoya, A. O. E-Cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma. Mod. Pathol. 24, 241–247 (2011).PubMed

108.

Al-Ahmadie, H. A. et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat. Genet. 48, 356–358 (2016).PubMedPubMedCentral

109.

Fong, A. et al. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation. Am. J. Clin. Pathol. 120, 93–100 (2003).PubMed

110.

Babjuk, M. et al. EAU guidelines non-muscle-invasive urothelial carcinoma bladder: update 2013. Eur. Urol. 64, 639–653 (2013).PubMed

111.

Abd El-Latif, A., Watts, K. E., Elson, P., Fergany, A. & Hansel, D. E. The sensitivity of initial transurethral resection or biopsy of bladder tumor(s) for detecting bladder cancer variants on radical cystectomy. J. Urol. 189, 1263–1267 (2013).PubMed

112.

Weizer, A. Z. et al. Multiple adverse histological features increase the odds of under staging T1 bladder cancer. J. Urol. 182, 59–65 (2009).PubMed

113.

Ge, P., Wang, Z.-C., Yu, X., Lin, J. & He, Q. Sensitivity of initial biopsy or transurethral resection of bladder tumor(s) for detecting histological variants on radical cystectomy. BMC Urol. 15, 46 (2015).PubMedPubMedCentral

114.

Burger, M. et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64, 846–854 (2013).PubMed

115.

Naito, S. et al. The clinical research office of the endourological society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection of bladder tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur. Urol. 70, 506–515 (2016).PubMed

116.

Shapur, N. K. et al. Is radical cystectomy mandatory in every patient with variant histology of bladder cancer. Rare Tumors 3, e22 (2011).PubMedPubMedCentral

117.

Gofrit, O. N. et al. The response of variant histology bladder cancer to intravesical immunotherapy compared to conventional cancer. Front. Oncol. 6, 43 (2016).PubMedPubMedCentral

118.

Willis, D. L. et al. Clinical outcomes of cT1 micropapillary bladder cancer. J. Urol. 193, 1129–1134 (2015).PubMed

119.

Ghoneim, I. A. et al. Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder. Urology 77, 867–870 (2011).PubMed

120.

Vourganti, S. et al. Low grade micropapillary urothelial carcinoma, does it exist? - Analysis of management and outcomes from the Surveillance, Epidemiology and End Results (SEER) Database. J. Cancer 4, 336–342 (2013).PubMedPubMedCentral

121.

Miller, J. S. & Epstein, J. I. Noninvasive urothelial carcinoma of the bladder with glandular differentiation: report of 24 cases. Am. J. Surg. Pathol. 33, 1241–1248 (2009).PubMed

122.

Chan, T. Y. & Epstein, J. I. In situ adenocarcinoma of the bladder. Am. J. Surg. Pathol. 25, 892–899 (2001).PubMed

123.

Seisen, T., Compérat, E., Léon, P. & Rouprêt, M. Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. Curr. Opin. Urol. 24, 524–531 (2014).PubMed

124.

Bansal, A., Kumar, N. & Sharma, S. C. Sarcomatoid variant of urothelial carcinoma of the urinary bladder. J. Cancer Res. Ther. 9, 571–573 (2016).

125.

Fatima, N. et al. Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. Can. J. Urol. 22, 7783–7787 (2015).PubMed

126.

Raspollini, M. R. et al. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum. Pathol. 42, 1149–1158 (2011).PubMed

127.

Xylinas, E. et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur. J. Cancer. 49, 1889–1897 (2013).PubMed

128.

Fairey, A. S. et al. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urol. Oncol. 32, 110–116 (2014).PubMed

129.

Monn, M. F. et al. The changing reality of urothelial bladder cancer: should non-squamous variant histology be managed as a distinct clinical entity? BJU Int. 116, 236–240 (2015).PubMed

130.

Ismaili, N. A rare bladder cancer - small cell carcinoma: review and update. Orphanet J. Rare Diseases 6, 75 (2011).

131.

Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).PubMed

132.

International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171–2177 (2011).

133.

Pokuri, V. K. et al. Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma. Clin. Genitourinary Cancer 14, e59–e65 (2016).

134.

Culp, S. H. et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J. Urol. 191, 40–47 (2014).PubMed

135.

Moschini, M. et al. Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy. Clin. Genitourinary Cancer 15, e267–e273 (2016).

136.

Black, P. C., Brown, G. A. & Dinney, C. P. N. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol. Oncol. 27, 3–7 (2009).PubMed

137.

Meeks, J. J. et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 111, E325–E330 (2013).PubMed

138.

Kassouf, W. et al. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of the university of Texas M. D. Anderson cancer center experience. Cancer 110, 764–769 (2007).PubMed

139.

Gad el Mawla, N. et al. A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder. Ann. Oncol. 2, 137–140 (1991).PubMed

140.

Scosyrev, E. et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 108, 693–699 (2011).PubMed

141.

Lynch, S. P. et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur. Urol. 64, 307–313 (2013).PubMed

142.

Siefker-Radtke, A. O. et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J. Clin. Oncol. 27, 2592–2597 (2009).PubMedPubMedCentral

143.

Bex, A., de Vries, R., Pos, F., Kerst, M. & Horenblas, S. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J. Urol. 27, 101–106 (2009).PubMed

144.

Schreiber, D. et al. Characterization and outcomes of small cell carcinoma of the bladder using the surveillance, epidemiology, and end results database. Am. J. Clin. Oncol. 36, 126–131 (2013).PubMed

145.

Masson-Lecomte, A. et al. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World J. Urol. 33, 1087–1093 (2015).PubMed

146.

Sui, W. et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J. Urol. 35, 1055–1061 (2016).PubMed

147.

Willis, D. L., Porten, S. P. & Kamat, A. M. Should histologic variants alter definitive treatment of bladder cancer? Curr. Opin. Urol. 23, 435–443 (2013).PubMed

» This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Medicine Matters Oncology

Abstract